BIIB - Biogen Inc.
| Previous Close | 320.14 |
| Open | 319.60 |
| Bid | 316.780 x 1800 |
| Ask | 317.120 x 900 |
| Day's Range | 315.86 - 320.50 |
| 52 Week Range | 249.17 - 388.67 |
| Volume | 345,901 |
| Avg. Volume | 1,284,098 |
| Market Cap | 64.058B |
| Beta (3Y Monthly) | 1.99 |
| PE Ratio (TTM) | 20.78 |
| EPS (TTM) | 15.297 |
| Earnings Date | Jan 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 388.35 |
Zacks•2 hours ago5 Incredible ETFs & Stocks to Buy on the Dip
The dips might charge up investors to snap up stocks and ETFs on the cheap for outsized gains heading into Christmas.
- Zacks•3 hours ago
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Market Realist•4 hours agoDo Analysts See Any Upside for Biogen Stock?
Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.
- Benzinga•22 hours ago
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Applied Genetic Technologies Corp (NASDAQ: AGTC ), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis ...
Market Realist•23 hours agoTaking Stock of Biogen’s Recent Performance
Biogen’s (BIIB) core growth areas include multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, and neuromuscular disorders. It’s also focused on areas such as pain, ophthalmology, neuropsychiatry, and acute neurology.
Market Realist•23 hours agoA Closer Look at Biogen’s Gross Margin Trends
In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.
Zacks•yesterdayThe Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
- Benzinga•yesterday
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
- InvestorPlace•2 days ago
5 Pharma Stocks That Could Cure Ailing Portfolios in 2019
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
- Zacks•2 days ago
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
A low key week for the biotech sector with focus on regular pipeline updates.
Market Realist•2 days agoDo Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
Market Realist•2 days agoWhat Regeneron Pharmaceuticals’ Bottom Line Indicates
In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.
Zacks•2 days agoThe Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
Market Realist•3 days agoUnderstanding Regeneron Pharmaceuticals’ Operational Performance
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.
Market Realist•3 days agoRegeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.
- Zacks•3 days ago
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Markit•3 days agoSee what the IHS Markit Score report has to say about Biogen Inc.
Biogen Inc NASDAQ/NGS:BIIB
- GlobeNewswire•8 days ago
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.
- Zacks•10 days ago
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
- Zacks•11 days ago
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
- Investor's Business Daily•14 days ago
Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar
Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.
Market Realist•14 days agoHow Much Upside Wall Street Sees in Sangamo Stock
In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.
Market Realist•14 days agoTaking Stock of Sangamo’s Financial Performance
Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.
Market Realist•14 days agoAnalyzing Sangamo Therapeutics’ Operational Performance
Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.
